OCT Therapies & Research

Therapies

Our Distinctive Edge

Cell-free Technology
We're passionate about the future of regenerative medicine and the incredible promise it holds. Through the power of cutting-edge cell-free technology and therapy, we are dedicated to the repair of tissues and organs at the cellular level.
By harnessing the power of proteins, cytokines , and growth factors, our cell-free technology offers a new frontier in wound care— one that’s non-invasive, highly effective, and designed to deliver real results. Our products work in harmony with the body to create a healing environment that stimulates cellular proliferation, angiogenesis, and overall tissue repair for faster, more effective results.
Ethical Manufacturing
At OCT, we’re committed to ethical manufacturing practices that prioritise animal welfare and sustainability. With two patents granted for our xeno-free stem cell technology, we avoid using any animal-derived products in our entire manufacturing process. We do not test on animals. This makes our products cruelty-free. Unlike many other companies that use Fetal Bovine Serum (FBS) in their cell culture processes, we refuse to support the inhumane harvesting of bovine fetuses from pregnant cows without any form of anaesthesia. Instead, we use a modified human serum that’s ethically sourced from registered blood banks and adapted to our requirements. Other ethical practices include sourcing the umbilical cords with Institutional Ethics Committee approvals and documented informed consent from the donors. This is also a sustainable and endless source of raw material for all the regenerative products we manufacture.It is also a non-invasive and safe procedure for the mother and baby. The use of ethically sourced materials and sustainable practices is crucial for the development of safe and effective regenerative products that benefits society as a whole.
Biocompatible products
At OCT, we’re proud to offer completely biocompatible products that are both effective and ethical. By using a modified human serum, we’re able to ensure that all of our products are safe and compatible with the human body—without sacrificing our commitment to animal welfare and sustainability. In addition to our commitment to ethical and sustainable practices, we also prioritise efficacy and safety. Our products undergo rigorous testing and quality control measures to ensure that they are both safe and effective for their intended use. We believe that by combining ethical and sustainable practices with a focus on efficacy and safety, we can provide products for the ethical and conscientious consumer without any compromise on values. Biocompatible : the ability of a substance or material, such as OCT’s products, to be compatible with living tissue or living systems, without causing harm or toxic effects

Our Story

It’s in our “culture”!

We specialise in developing stem cell-based and cell-free applications for medical conditions where there is an urgent and unmet need.

We believe that the medicines of the future will align towards cell-based and cell-free approaches or regenerative medicine, and to that end, we develop ethical and sustainable solutions.

Our Vision

Be globally recognised as a leading biotechnology company focused on ethical and sustainable stem cell-based and cell-free solutions for critical needs

Our Mission

Research and development backed by scientific rigour, validated processes, and proven efficacy with the highest levels of quality and safety in manufacturing

Our Journey

2013

  • OCT Therapies and Research Pvt. Ltd. incorporated.

2014

  • IP filed.
  • Animal PoC.

2015

  • NAC-SCRT Regstn.
  • BIRAC Funding.
  • Hair PoC.

2016

  • CDSCO Test License.
  • DSIR Recognition.

2017

  • IP filed
  • ISO Certfn.
  • DIPP Certfn.
  • BIRAC project completed.

2018

  • CCAMP Seed Funding International patent filed.

2019

  • Manufacturing facility ready
  • CDSCO Test License obtained
  • National phase entry in UK, USA, Canada, Malaysia

2021

  • CDSCO approval for stem-cell cosmetic & CDSCO test license for pharma product.
  • India patent granted

2022-23

  • Patents granted in UK and Malaysia
  • New IP filed

2026

  • Clinical trials for advanced wound care set to commence.

Supported by

Accredited by

Collaborations with

Our Team

Dr. Caroline Mathen

Founder and CEO

Mathen Mathew

Director

Wilfrid D’Souza

Head of Quality Control

Our Lab

Our facility is compliant with Good Manufacturing Practices which helps in ensuring the best quality products for our customers

Our Achievements

September 2015

Won prestigious BIG Grant under BIRAC-DBT for the proposal titled ‘Establishment of a Mesenchymal Stem Cell Bank as an Alternative Skin Bank’

April 2018

Won C-CAMP SEED funding, an equity-based funding by the Government of India

June 2022

Showcased among India’s 75 top biotech products, launched by Prime Minister Narendra Modi on the occasion of India’s 75th Independence Day (Azadi ka Amrit Mahotsav) in Delhi, India

November 2022

Showcased by C-Camp and Dr Renu Swaroop at People’s Festival of Innovations in Delhi, India

January-February 2023

UK and Malaysia patents granted

Contact

Manufacturing Facility and R & D Laboratory

Unit 7B, 1st Floor, Tikitar Industrial Estate, Bhandup Village Road, Off LBS Marg, Bhandup West, Mumbai 400078, India

Contact

+91-22-4603 3319

Email

customercare@octtherapies.com